Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.22
NAS:DXCM's Cash-to-Debt is ranked higher than
97% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. NAS:DXCM: 2.22 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:DXCM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: 19.85 Max: No Debt
Current: 2.22
Equity-to-Asset 0.60
NAS:DXCM's Equity-to-Asset is ranked higher than
67% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:DXCM: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:DXCM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.63  Med: 0.72 Max: 0.92
Current: 0.6
-0.63
0.92
Piotroski F-Score: 3
Altman Z-Score: 17.62
Beneish M-Score: -3.71
WACC vs ROIC
5.72%
-58.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -14.20
NAS:DXCM's Operating Margin % is ranked lower than
58% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NAS:DXCM: -14.20 )
Ranked among companies with meaningful Operating Margin % only.
NAS:DXCM' s Operating Margin % Range Over the Past 10 Years
Min: -1008.77  Med: -57.24 Max: -8.29
Current: -14.2
-1008.77
-8.29
Net Margin % -14.70
NAS:DXCM's Net Margin % is ranked lower than
57% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NAS:DXCM: -14.70 )
Ranked among companies with meaningful Net Margin % only.
NAS:DXCM' s Net Margin % Range Over the Past 10 Years
Min: -991.53  Med: -56.57 Max: -8.64
Current: -14.7
-991.53
-8.64
ROE % -33.86
NAS:DXCM's ROE % is ranked lower than
62% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. NAS:DXCM: -33.86 )
Ranked among companies with meaningful ROE % only.
NAS:DXCM' s ROE % Range Over the Past 10 Years
Min: -259.33  Med: -45.51 Max: -19.97
Current: -33.86
-259.33
-19.97
ROA % -23.63
NAS:DXCM's ROA % is ranked lower than
60% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NAS:DXCM: -23.63 )
Ranked among companies with meaningful ROA % only.
NAS:DXCM' s ROA % Range Over the Past 10 Years
Min: -117.86  Med: -46.68 Max: -14.59
Current: -23.63
-117.86
-14.59
ROC (Joel Greenblatt) % -58.48
NAS:DXCM's ROC (Joel Greenblatt) % is ranked lower than
58% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NAS:DXCM: -58.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:DXCM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -828.4  Med: -228.52 Max: -47.64
Current: -58.48
-828.4
-47.64
3-Year Revenue Growth Rate 45.00
NAS:DXCM's 3-Year Revenue Growth Rate is ranked higher than
94% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NAS:DXCM: 45.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:DXCM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 38.1 Max: 103.1
Current: 45
0
103.1
3-Year EBITDA Growth Rate 24.10
NAS:DXCM's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NAS:DXCM: 24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:DXCM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -25.8 Max: 24.1
Current: 24.1
0
24.1
3-Year EPS without NRI Growth Rate 22.90
NAS:DXCM's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. NAS:DXCM: 22.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:DXCM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -40  Med: -15.7 Max: 47.3
Current: 22.9
-40
47.3
GuruFocus has detected 2 Warning Signs with DexCom Inc $NAS:DXCM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:DXCM's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

DXCM Guru Trades in Q2 2016

John Paulson 123,500 sh (+199.03%)
Steven Cohen 261,000 sh (+1.20%)
Andreas Halvorsen Sold Out
Mario Gabelli 41,900 sh (-3.46%)
Ron Baron 901,677 sh (-17.46%)
RS Investment Management 309,651 sh (-57.82%)
Jim Simons 341,806 sh (-58.21%)
» More
Q3 2016

DXCM Guru Trades in Q3 2016

George Soros 2,576 sh (New)
Jim Simons Sold Out
Mario Gabelli 41,600 sh (-0.72%)
Ron Baron 851,477 sh (-5.57%)
Steven Cohen 183,600 sh (-29.66%)
John Paulson 43,500 sh (-64.78%)
» More
Q4 2016

DXCM Guru Trades in Q4 2016

Jim Simons 137,643 sh (New)
John Paulson 293,200 sh (+574.02%)
George Soros 5,300 sh (+105.75%)
Steven Cohen 192,600 sh (+4.90%)
Steven Cohen 200,000 sh (unchged)
Ron Baron 839,027 sh (-1.46%)
Mario Gabelli 37,300 sh (-10.34%)
» More
Q1 2017

DXCM Guru Trades in Q1 2017

Jim Simons 295,143 sh (+114.43%)
Ron Baron 789,027 sh (-5.96%)
Mario Gabelli 34,000 sh (-8.85%)
John Paulson 240,700 sh (-17.91%)
George Soros 2,800 sh (-47.17%)
Steven Cohen 44,657 sh (-76.81%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 3841
Compare:NAS:INCR, NYSE:BIO, NYSE:PKI, NAS:ICLR, NAS:PRAH, OTCPK:CZMWY, NAS:VWR, NAS:QGEN, NYSE:CRL, NAS:BRKR, OTCPK:SWTUY, NYSE:ALR, NAS:PRXL, OTCPK:BMXMF, NAS:EXAS, OTCPK:ERFSF, NAS:NEOG, NAS:AXDX, NAS:MYGN, NAS:FMI » details
Traded in other countries:DC4.Germany,
Headquarter Location:USA
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company's product line includes SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body's glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.

Guru Investment Theses on DexCom Inc

Baron Funds Comments on DexCom Inc. - Jan 14, 2016

Another health care holding, DexCom, Inc., (NASDAQ:DXCM) sells a continuous glucose monitoring system for diabetics. Although this is an unusual investment for the portfolio because of its extended trading multiple, we think DexCom’s fundamentals justify our investment. Over the last three years, DexCom has launched a series of new products driving a dramatic acceleration in revenue growth. We believe the company’s new product pipeline remains robust and will lead to further adoption among the growing population of diabetics.



From the Baron Funds Small Cap Fund winter newsletter 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on DexCom Inc. - Aug 19, 2015

DexCom, Inc. (NASDAQ:DXCM) sells a continuous glucose monitoring device for insulin dependent diabetes. DexCom reported very strong results. Revenues grew 55% in the quarter, and the company reiterated guidance for continued exceptional growth. The company launched its “share” system, which allows parents or spouses to receive the users’ blood glucose data from the users’ handheld devices, an important new feature. And they filed for approval of their next generation offering that will transmit data directly to a smartphone, eliminating the need to carry a receiver. Strong new patient starts, more accurate and feature rich products, and an expanding addressable market make for a company that, we believe, can grow rapidly for a considerable time go forward.



From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about DexCom Inc

Weekly CFO Sells Highlights Insiders sell holdings in Fidelity National Financial, DexCom and Facebook
According to GuruFocus Insider Data, the recent CFO sells were: Fidelity National Financial Inc. (NYSE:FNF), DexCom Inc. (NASDAQ:DXCM) and Facebook Inc. (NASDAQ:FB). Read more...

Ratios

vs
industry
vs
history
PB Ratio 21.37
DXCM's PB Ratio is ranked lower than
97% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. DXCM: 21.37 )
Ranked among companies with meaningful PB Ratio only.
DXCM' s PB Ratio Range Over the Past 10 Years
Min: 3.88  Med: 19.01 Max: 194.65
Current: 21.37
3.88
194.65
PS Ratio 9.69
DXCM's PS Ratio is ranked lower than
84% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. DXCM: 9.69 )
Ranked among companies with meaningful PS Ratio only.
DXCM' s PS Ratio Range Over the Past 10 Years
Min: 6.16  Med: 14.54 Max: 1114.21
Current: 9.69
6.16
1114.21
Price-to-Operating-Cash-Flow 102.18
DXCM's Price-to-Operating-Cash-Flow is ranked lower than
98% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. DXCM: 102.18 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DXCM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 89.37  Med: 154.38 Max: 1409.38
Current: 102.18
89.37
1409.38
EV-to-EBIT -68.88
DXCM's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. DXCM: -68.88 )
Ranked among companies with meaningful EV-to-EBIT only.
DXCM' s EV-to-EBIT Range Over the Past 10 Years
Min: -391.9  Med: -15.7 Max: -1.6
Current: -68.88
-391.9
-1.6
EV-to-EBITDA -83.99
DXCM's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. DXCM: -83.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
DXCM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -764.5  Med: -16.9 Max: -1.7
Current: -83.99
-764.5
-1.7
Current Ratio 1.92
DXCM's Current Ratio is ranked higher than
54% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. DXCM: 1.92 )
Ranked among companies with meaningful Current Ratio only.
DXCM' s Current Ratio Range Over the Past 10 Years
Min: 1.92  Med: 3.95 Max: 23.47
Current: 1.92
1.92
23.47
Quick Ratio 1.65
DXCM's Quick Ratio is ranked higher than
54% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. DXCM: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
DXCM' s Quick Ratio Range Over the Past 10 Years
Min: 1.65  Med: 3.48 Max: 23.47
Current: 1.65
1.65
23.47
Days Inventory 81.53
DXCM's Days Inventory is ranked higher than
50% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. DXCM: 81.53 )
Ranked among companies with meaningful Days Inventory only.
DXCM' s Days Inventory Range Over the Past 10 Years
Min: 35.66  Med: 54.23 Max: 81.53
Current: 81.53
35.66
81.53
Days Sales Outstanding 52.31
DXCM's Days Sales Outstanding is ranked lower than
53% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. DXCM: 52.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
DXCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.96  Med: 59.63 Max: 71.25
Current: 52.31
16.96
71.25
Days Payable 32.34
DXCM's Days Payable is ranked lower than
57% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. DXCM: 32.34 )
Ranked among companies with meaningful Days Payable only.
DXCM' s Days Payable Range Over the Past 10 Years
Min: 21.26  Med: 31.59 Max: 56.11
Current: 32.34
21.26
56.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
DXCM's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. DXCM: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DXCM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -137.6  Med: -14.7 Max: -4.6
Current: -5.3
-137.6
-4.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 41.98
DXCM's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. DXCM: 41.98 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DXCM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.88  Med: 23.52 Max: 53.03
Current: 41.98
4.88
53.03
Price-to-Tangible-Book 22.28
DXCM's Price-to-Tangible-Book is ranked lower than
93% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. DXCM: 22.28 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DXCM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.69  Med: 16.34 Max: 143.95
Current: 22.28
4.69
143.95
Price-to-Intrinsic-Value-Projected-FCF 153.00
DXCM's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. DXCM: 153.00 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DXCM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 69.42  Med: 176.1 Max: 282.77
Current: 153
69.42
282.77
Price-to-Median-PS-Value 0.67
DXCM's Price-to-Median-PS-Value is ranked higher than
69% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. DXCM: 0.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DXCM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.01 Max: 2027
Current: 0.67
0.55
2027
Earnings Yield (Greenblatt) % -1.44
DXCM's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. DXCM: -1.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DXCM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.58  Med: 0 Max: 0
Current: -1.44
-1.58
0

More Statistics

Revenue (TTM) (Mil) $599.4
EPS (TTM) $ -1.03
Beta0.58
Short Percentage of Float9.44%
52-Week Range $57.68 - 96.38
Shares Outstanding (Mil)86.35

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 728 965 1,219
EPS ($) -0.68 0.18 0.97
EPS without NRI ($) -0.68 0.18 0.97
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for DXCM

Headlines

Articles On GuruFocus.com
7 of the Worst-Performing Stocks in Gurus' Portfolios Apr 14 2017 
Weekly CFO Sells Highlight Jun 28 2016 
Baron Funds Comments on DexCom Inc. Jan 14 2016 
Investing for Lower Risk Long-Term Growth in a Volatile Asset Class - Baron Funds Winter Newsletter Jan 14 2016 
Top Weekly Insider Sells Highlights Sep 15 2015 
Weekly CFO Sells Highlight: Gilead Sciences, DexCom, and Palo Alto Networks Sep 13 2015 
Panic-Proofing the Small Investor Aug 26 2015 
Baron Funds Comments on DexCom Inc. Aug 19 2015 
Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc. Jul 20 2015 
Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM Jul 14 2015 

More From Other Websites
ETFs with exposure to DexCom, Inc. : May 18, 2017 May 18 2017
Cramer Remix: Here are the winners after Wednesday’s mark... May 17 2017
Will Wearable Technology Make Us Healthier? May 16 2017
Edited Transcript of DXCM earnings conference call or presentation 2-May-17 8:30pm GMT May 16 2017
What's Alphabet Got to Do With Healthcare? May 15 2017
DexCom Announces Upcoming Conference Presentation May 15 2017
DexCom Prices Offering of $350 Million of 0.75% Convertible Senior Notes May 08 2017
DexCom Announces Proposed Offering of $300 Million of Convertible Senior Notes May 08 2017
DexCom, Inc. :DXCM-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 May 04 2017
Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System now Compatible with Apple Watches in... May 04 2017
DexCom, Inc. – Value Analysis (NASDAQ:DXCM) : May 3, 2017 May 03 2017
Here's Why DexCom Stock Is Tanking Today May 03 2017
DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss May 03 2017
DexCom reports 1Q loss May 02 2017
DexCom, Inc. Reports First Quarter 2017 Financial Results May 02 2017
DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : May 2, 2017 May 02 2017
Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More May 01 2017
Sohn Investment Conference: Investing for good Apr 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat